Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Operas
6
Administración de personal
5
Internet en la educación
4
Enseñanza con ayuda de computadoras
3
Historia
3
Música barroca
3
Música instrumental
3
Administración
2
Autores mexicanos
2
Capital humano
2
Cirugía
2
Derechos humanos
2
Diseño
2
Educación
2
Educación superior
2
Innovaciones tecnológicas
2
Misa (Música)
2
Motetes
2
Música - Siglo XIX
2
Música de cámara
2
Música orquestal
2
Música para órgano
2
Música sacra
2
Sinfonías
2
Sonatas (Violín)
2
Suites (Violín)
2
Adaptabilidad (Psicología)
1
Aeronáutica en agricultura
1
Anatomía
1
Antigüedades
1
-
801por Zhu, Wentao, Zheng, Miaomiao, Xia, Panpan, Hong, Wanglong, Ma, Guoqiang, Shen, Aizong“…CONCLUSIONS: Palbociclib plus fulvestrant is unlikely to be cost-effective in comparison with placebo plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer.…”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
802por Engel-Nitz, Nicole M, Johnson, Mary G, Johnson, Michael P, Cha-Silva, Ashley S, Kurosky, Samantha K, Liu, Xianchen“…PURPOSE: To assess adherence and persistence with palbociclib therapy in patients with HR+/HER2- metastatic breast cancer (mBC) in a US real-world setting. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
803por Davis, Andrew A., Luo, Jingqin, Zheng, Tiantian, Dai, Chao, Dong, Xiaoxi, Tan, Lu, Suresh, Rama, Ademuyiwa, Foluso O., Rigden, Caron, Rearden, Timothy P., Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Tandra, Pavan K., Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel F., Peterson, Lindsay L., Wang, Xiaohong, Luo, Shujun J., Zhou, Kemin, Du, Pan, Jia, Shidong, King, Bonnie L., Krishnamurthy, Jairam, Ma, Cynthia X.“…EXPERIMENTAL DESIGN: ctDNA was isolated from 216 plasma samples collected from 51 patients with hormone receptor–positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC) on a phase II trial of palbociclib combined with letrozole or fulvestrant (NCT03007979). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
804por Gogate, Anagha, Ranjan, Sandip, Kumar, Amit, Bhandari, Hitesh, Papademetriou, Eros, Kim, Inkyu, Potluri, Ravi“…They may be considered as valid surrogates for OS in HR+/HER2- breast cancer.…”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
805por Schmidt, Felix N., Schmidt, Constantin, Delsmann, Julian, Amling, Michael, Barvencik, Florian“…These groups were compared by means of bone microarchitecture using high-resolution peripheral quantitative computed tomography (HR-pQCT) and simulated mechanical performance utilizing finite element analysis (FEA). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
806“…Hormone receptor-positive breast cancer (HR+ BC) cells depend on estrogen and its receptor, ER. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
807por Yang, Yang, He, Yingjian, Fan, Zhaoqing, Chen, Xue, Liu, Yiqiang, Zhang, Chao, Jiang, Hongchuan, Wang, Xin, Wang, Xiang, Xie, Fei, Wang, Shu, Luo, Bin, Kang, Hua, Wang, Tao, Jiang, Zefei, Yuan, Peng, Xu, Binhe, Xu, Ling, Liu, Yinhua, Li, Jinfeng, Xie, Yuntao, Wang, Tianfeng, Ouyang, Tao“…There are few studies focus on post-neoadjuvant treatment in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-)/lymph node-positive (LN+) breast cancer, a multi-center, open-label, randomized, controlled phase III trial was conducted to evaluate pathological response-guided non-cross-resistant adjuvant chemotherapy in patients with HR+/HER2-/LN+ breast cancer who were non-responsive to primary chemotherapy. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
808por Foldi, Julia, Tsagianni, Anastasia, Salganik, Max, Schnabel, Catherine A., Brufsky, Adam, van Londen, G. J., Pusztai, Lajos, Sanft, Tara“…METHODS: Women with stage I-III HR + breast cancer who had BCI testing after at least 3.5 years of adjuvant ET and ≥ 7 years of follow-up after diagnosis were included (n = 240). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
809“…MATERIALS/METHODS: The present study aimed to investigate the potential protective effects of red orange complex H extract (ROC) against ultraviolet (UV)-induced skin photoaging in Skh:HR-2 mice. ROC was orally administered at doses of 20, 40, and 80 mg/kg/day for 13 weeks, along with UV irradiation of the mice for 10 weeks. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
810por Parikh, Purvish, Babu, Govind, Singh, Randeep, Krishna, Vamshi, Bhatt, Amit, Bansal, Indu, Rajappa, Senthil, Sahoo, Tarini Prasad, Aggarwal, Shyam, Bapna, Ajay, Biswas, Ghanshyam, Somashekhar, SP, Bajpai, Jyoti, Maniar, Vashishtha, Desai, Sharad, Raja, T, Rath, Goura Kishor“…BACKGROUND: Precise prognostication is the key to optimum and effective treatment planning for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
811por Cherrada, Nezar, Elkhalifa Chemsa, Ahmed, Erol, Ebru, Günaydın Akyildiz, Aysenur, Oyku Dinc, Harika, Gheraissa, Noura, Ghemam Amara, Djilani, Rebiai, Abdelkrim, Abdel-Kader, Maged S., Messaoudi, Mohammed“…The bioactive compounds present in the plant were identified using LC-HR/MS analysis. The crude hydromethanolic extract (STM) and five fractions of S. tetragona, n-hexane (STH), dichloromethane (STD), ethyl acetate (STE), n-butanol (STB), and aqueous (STW) showed significant antioxidant activity in four different tests. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
812por Etikasari, Ria, Andayani, Tri Murti, Endarti, Dwi, Taroeno-Hariadi, Kartika Widayati“…Letrozole was found better than anastrozole (hazard ratio (HR)=4.342, 95% CI 0.95-19.95; p=0.038). Letrozole versus exemestane (HR=2.757, 95% CI 0.53-14.33; p=0,206) and anastrozole versus exemestane (HR=1.652, 95% CI 0.56-4.84; p=0.351) were found not significantly different. 5-y DFS rate of letrozole was better found (87.5%) than exemestane (73.7%) and anastrozole (61.4%). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
813“…Despite the development of HER2-targeted drugs, achieving favorable outcomes for patients with HR+/HER2+MBC remains challenging. This study utilized Bayesian Network Meta-analysis to compare the efficacy and safety of anti-HER2 combination regimens. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
814por Ozden, Eda Mehtap, Bingol, Zeynebe, Mutlu, Muzaffer, Karagecili, Hasan, Köksal, Ekrem, Goren, Ahmet C., Alwasel, Saleh H., Gulcin, İlhamiEnlace del recurso
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
815por Zhang, Yi, Zhang, Wei, Du, Hui, Qu, Xinfeng, Chen, Yun, Wang, Jianliu, Wu, Ruifang“…Direct association were showed between the severity of cervical lesions and the HPV viral loads reflected by CtV of hrHPV, HPV16, non-16/18 hrHPV and A9 group from both assays. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
816“…As an illustrative example, we focus on how to implement shared decision-making to address the needs of a patient with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer who is eligible for combination therapy with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
817“…This led to identification of two frequent EnvB alterations which allowed TVB receptor-binding but altered the pH-threshold of membrane fusion activation: a 13 amino acid deletion in the host range 1 (hr1) region of the surface (SU) EnvB subunit, and the A32V amino acid change within the fusion peptide of the transmembrane (TM) EnvB subunit. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
818“…Importantly, GhMKK5-overexpressing plants displayed markedly elevated expression of reactive oxygen species-related and cell death marker genes, such as NtRbohA and NtCDM, and resulted in hypersensitive response (HR)-like cell death characterized by the accumulation of H(2)O(2). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
819por Ouchi, Motoshi, Suzuki, Tatsuya, Hashimoto, Masao, Motoyama, Masayuki, Ohara, Makoto, Suzuki, Kazunari, Igari, Yoshimasa, Watanabe, Kentaro, Nakano, Hiroshi, Oba, KenzoEnlace del recurso
Publicado 2012
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
820por Li, Nanxin, Hao, Yanni, Xie, Jipan, Lin, Peggy L., Koo, Valerie, Ohashi, Erika, Wu, Eric Q.“…Multivariate-adjusted Cox models showed that everolimus-based therapy was associated with significantly longer OS [hazard ratio (HR) = 0.37, 95% confidence interval (CI): 0.22–0.63], PFS (HR = 0.70, 95% CI = 0.50–0.97), and TOT (HR = 0.34, 95% CI: 0.25–0.45) than chemotherapy. …”
Publicado 2015
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto